Compare IPCA Labs with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SANOFI INDIA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SANOFI INDIA IPCA LABS/
SANOFI INDIA
 
P/E (TTM) x 25.0 40.9 61.0% View Chart
P/BV x 4.8 7.2 66.7% View Chart
Dividend Yield % 0.3 1.2 20.9%  

Financials

 IPCA LABS   SANOFI INDIA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
SANOFI INDIA
Dec-18
IPCA LABS/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,0426,840 15.2%   
Low Rs5904,630 12.7%   
Sales per share (Unadj.) Rs298.61,203.1 24.8%  
Earnings per share (Unadj.) Rs35.0165.3 21.2%  
Cash flow per share (Unadj.) Rs49.4209.9 23.6%  
Dividends per share (Unadj.) Rs3.0084.00 3.6%  
Dividend yield (eoy) %0.41.5 25.1%  
Book value per share (Unadj.) Rs247.1963.6 25.6%  
Shares outstanding (eoy) m126.3523.03 548.6%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.74.8 57.3%   
Avg P/E ratio x23.334.7 67.2%  
P/CF ratio (eoy) x16.527.3 60.4%  
Price / Book Value ratio x3.36.0 55.5%  
Dividend payout %8.650.8 16.9%   
Avg Mkt Cap Rs m103,108132,078 78.1%   
No. of employees `00013.43.3 407.2%   
Total wages/salary Rs m7,8744,068 193.6%   
Avg. sales/employee Rs Th2,807.08,393.8 33.4%   
Avg. wages/employee Rs Th585.81,232.4 47.5%   
Avg. net profit/employee Rs Th329.01,153.0 28.5%   
INCOME DATA
Net Sales Rs m37,73227,708 136.2%  
Other income Rs m577897 64.3%   
Total revenues Rs m38,30928,605 133.9%   
Gross profit Rs m6,9016,235 110.7%  
Depreciation Rs m1,8241,027 177.6%   
Interest Rs m1897 2,695.7%   
Profit before tax Rs m5,4656,098 89.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0422,292 45.5%   
Profit after tax Rs m4,4223,806 116.2%  
Gross profit margin %18.322.5 81.3%  
Effective tax rate %19.137.6 50.8%   
Net profit margin %11.713.7 85.3%  
BALANCE SHEET DATA
Current assets Rs m23,77815,922 149.3%   
Current liabilities Rs m10,9756,235 176.0%   
Net working cap to sales %33.935.0 97.1%  
Current ratio x2.22.6 84.8%  
Inventory Days Days10464 163.0%  
Debtors Days Days6621 315.9%  
Net fixed assets Rs m20,3687,539 270.2%   
Share capital Rs m253230 109.9%   
"Free" reserves Rs m30,97121,962 141.0%   
Net worth Rs m31,22422,192 140.7%   
Long term debt Rs m1,4090-   
Total assets Rs m45,50729,839 152.5%  
Interest coverage x30.0872.1 3.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.9 89.3%   
Return on assets %10.112.8 79.3%  
Return on equity %14.217.2 82.6%  
Return on capital %17.327.5 63.0%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,3087,587 228.1%   
Fx outflow Rs m6,2667,145 87.7%   
Net fx Rs m11,042442 2,498.2%   
CASH FLOW
From Operations Rs m4,9233,739 131.7%  
From Investments Rs m-1,563-731 213.8%  
From Financial Activity Rs m-1,832-1,972 92.9%  
Net Cashflow Rs m1,5281,036 147.5%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 11.4 14.4 79.2%  
FIIs % 25.3 14.6 173.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.5 165.7%  
Shareholders   36,892 15,184 243.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PANACEA BIOTECH  BIOCON   J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare IPCA LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Up; Telecom Stocks Rally(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.6% while the Hang Seng is up 0.9%.

Related Views on News

IPCA LABS at All Time High; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Nov 19, 2019 | Updated on Nov 19, 2019

IPCA LABS share price has hit an all time high at Rs 1,182 (up 1.1%). The BSE HEALTHCARE Index is up by 0.5%. Among the top gainers in the BSE HEALTHCARE Index today are IPCA LABS (up 1.1%) and ABBOTT INDIA (up 0.2%). The top losers include SUN PHARMA ADV. RES. and DISHMAN CARBOGEN AMCIS LTD .

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 19, 2019 11:11 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - ELDER PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS